aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of “Hold” by Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been given a consensus rating of “Hold” by the eight ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $17.00.

ATYR has been the topic of a number of research analyst reports. Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 26th. Finally, Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a report on Saturday, June 27th.

Insider Activity at aTyr Pharma

In other news, Director Paul Schimmel acquired 100,000 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $50,000.00. Following the acquisition, the director directly owned 779,143 shares in the company, valued at $389,571.50. This trade represents a 14.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.75% of the stock is currently owned by company insiders.

Institutional Trading of aTyr Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of ATYR. California State Teachers Retirement System acquired a new position in aTyr Pharma during the second quarter valued at approximately $28,000. Renaissance Technologies LLC acquired a new position in shares of aTyr Pharma during the 1st quarter valued at $32,000. ADAR1 Capital Management LLC lifted its holdings in shares of aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after acquiring an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in aTyr Pharma during the 4th quarter worth $41,000. Finally, Legal & General Group Plc purchased a new stake in aTyr Pharma during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Price Performance

NASDAQ ATYR opened at $0.58 on Friday. aTyr Pharma has a 12 month low of $0.40 and a 12 month high of $7.29. The company has a 50-day moving average of $0.57 and a 200-day moving average of $0.74. The company has a market cap of $57.04 million, a P/E ratio of -0.80 and a beta of 0.52.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. As a group, equities research analysts anticipate that aTyr Pharma will post -0.66 EPS for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.